Course of Multimodal Therapy and Genetic Profile of Hereditary Leiomyomatosis and Renal Cell Carcinoma with Early Recurrence during Adjuvant Therapy after Radical Nephrectomy: A Case Report
This case highlights the potential efficacy of combining tyrosine kinase inhibitor therapy with SBRT in managing aggressively progressive HLRCC.
Authors
- Hiromichi Katayama (ORCID: https://orcid.org/0000-0001-8339-5164)
- Tomonori Sato (ORCID: https://orcid.org/0000-0001-5659-6809)
- Satoko Sato
- Naoki Kawamorita (ORCID: https://orcid.org/0000-0001-6175-3063)
- Yohei Satake (ORCID: https://orcid.org/0000-0003-3961-1004)
- Takuro Goto
- Takuma Sato (ORCID: https://orcid.org/0000-0002-2213-3117)
- Hidekazu Shirota (ORCID: https://orcid.org/0000-0001-9154-9004)
- Yoshihide Kawasaki (ORCID: https://orcid.org/0000-0001-6425-3574)
- Akihiro Ito (ORCID: https://orcid.org/0000-0003-0908-8929)
- Hiroshi Masuda (ORCID: https://orcid.org/0000-0001-5890-6647)
Institutions
- Tohoku University (JP)
- Tohoku University Hospital (JP)
Publication Details
- Journal
- Urologia Internationalis
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1159/000547393
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00